我的购物车

HEK293/Human ASGR1 Stable Cell Line

用户评价
货号-规格
价格
Qty.
合计0件 产品金额0
0
加入购物车

产品详情

    1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
    2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
    3. Comprehensive application data to support assay development and validation
    4. Full tracible record, stringent quality control and validated cell passage stability
    5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
    6. Global commercial license assistance whenever regulatory filing is required
  • 描述(Description)

    HEK293/Human ASGR1 Stable Cell Line

  • 应用说明(Application)

    • Binding assay by FACS and cell based ELISA.

  • 生长特性(Growth Properties)

    Adherent

  • 筛选标记(Selection Marker)

    Hygromycin B (100 μg/mL)

  • 培养基(Complete Growth Medium)

    DMEM medium + 10% FBS

  • 冻存液(Freeze Medium)

    10% DMSO + 90% FBS

  • 装量(Quantity)

    1 vial contains at least 5x10^6 cells in 1 ml of 10% DMSO in FBS.

  • 存储(Storage)

    Frozen in liquid nitrogen.

  • 支原体检测(Mycoplasma Testing)

    Negative

  • 无菌检测(Sterility Testing)

    Negative

  • 使用说明(Instructions for Use)

    See data sheet for detailed culturing and assay protocol.

  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

数据展示

  • Receptor Assay

     ASGR1 FACS

    Fig. FACS analysis of ASGR1 on HEK293/Human ASGR1 Stable Cell Line.
    FACS assay shows that Anti-ASGR1 Antibody can bind to HEK293/Human ASGR1 Stable Cell Line. HEK293/Human ASGR1 Stable Cell Line was red line, Negative control HEK293 cells was grey line (QC tested).

    Protocol
*如有相关细胞池需求请联系我们

用户评价
发表评论

背景介绍

ASGPR, a transmembrane C-type lectin, recognizes a wide variety of ligands that contain either terminal galactose (Gal) or N-acetylgalactosamine (GalNAc) residues and has been identified as a highly selective receptor on hepatocytes. The ASGR is composed of both a major (ASGR1) and minor subunit (ASGR2). ASGR1 has been shown to be efficiently targeted to the plasma membrane and to undergo constitutive endocytosis and recycling and found mainly expressed in the human liver.

重要声明

  • Limited Use&License Disclosure

    BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

    1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
    2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
    3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.

前沿进展

 
药物研发进展
  • 英文全称:

    Asialoglycoprotein receptor 1

  • 中文全称:

    去唾液酸糖蛋白受体-1

  • 种类:

  • 上市药物数量:

    0 详情

  • 临床药物数量:

    1 详情

  • 最高研发阶段:

    临床一期

联系我们
项目合作
查看更多项目
  • 产品基础信息
  • 产品详情
  • 数据展示
  • 用户评价
  • 背景介绍
  • 重要声明